openPR Logo
Press release

Companion Diagnostic Tests in Oncology Market to Witness Increase in Revenues by 2025

11-10-2017 11:03 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Companion Diagnostic Tests in Oncology Market to Witness

According to a TMR analyst, “The global market for companion diagnostic tests in oncology is anticipated to rise at an outstanding 16.8% CAGR from 2017 to 2025. Rising from a valuation of US$3.5 bn in 2016, the market is likely to touch US$13.6 bn by 2025.” The application of companion diagnostic tests in oncology will be largely in detecting breast cancer. This is anticipated to provide the much needed push to the segment of breast cancer over the years ahead. It is expected to thus exhibit a 17.0% CAGR over the course of the forecast period. Region-wise, the global market for companion diagnostic tests in oncology is likely to be dominated by North America with an approximate share of 37.5% by 2025. The high acceptance rate of novel technologies in the region is one of the core reasons behind the dominance of North America on the regional front.

Read Report Overview @ https://www.transparencymarketresearch.com/companion-diagnostic-tests-market.html

The developing need for personalized healthcare alongside targeted treatments have expanded the development of the worldwide companion diagnostic tests in oncology market. The pharmaceutical industry is step by step advancing toward creating particular treatments to treat various sorts of chronic diseases such as cancer. The take-up of companion diagnostic tests and biomarkers have empowered human services suppliers to offer a scope of appropriate treatments to the patients, in this manner guaranteeing quicker recuperating time. High pervasiveness of malignancy, expanding danger of growth, way of life changes, and regular event of ailments, for instance, Hepatitis are relied upon to drive the worldwide market.

The worldwide market for companion diagnostic tests in oncology is likewise profiting by the remarkable diminishment in the cost of drug discovery because of selection of companion diagnostics. These diagnostics are utilized as a part of the procedure of drug discovery as they diminish the time spent in clinical trials by conveyance quicker outcomes in a proficient and successful way. This factor is surveyed to assume an instrumental part in characterizing the direction of the worldwide market for companion diagnostic tests in oncology. The developing concerns about neglected restorative needs are additionally anticipated to boost the demand for companion diagnostic tests in oncology in the coming years as pharmaceutical organizations will concentrate on innovative work to present new medications.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4684

The postponed procedures of endorsements for targeted therapies are relied upon to hamper the development of the worldwide companion diagnostic tests in oncology. Moreover, the inconvenience repayment situation has likewise discouraged the worldwide market in the course of recent years. The scattered interest of partners in the worldwide market is likewise going about as an obstruction to the growth of the market.

The degree of competition in the global companion diagnostic tests in oncology market for is likely to range from moderate to high owing to the fact that numerous manufacturers are looking forward to collaborate with several pharmaceutical manufacturers, states Transparency Market Research (TMR) in a research report. Moreover, the rising number of vendors in the market with several cutting edge technologies is also anticipated to put the position of established players at stake in the years ahead. The leading three players namely Agilent Technologies Inc., Abbott Laboratories, and Illumina Inc., accounted for a share of 23% in the global market for companion diagnostics tests in oncology in 2016. These vendors are also anticipated to concentrate on partnerships and product innovation to stay competitive in the market in the years ahead.

Buy Full Companion Diagnostic Tests in Oncology Market Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=4684

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Companion Diagnostic Tests in Oncology Market to Witness Increase in Revenues by 2025 here

News-ID: 810889 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Companion

Companion Animal Drugs - Key Market Statistics
Companion animals are pets kept primarily for company, entertainment, and safety. Owners of companion animals consider them to be family, friends, and confidants. Dogs, cats, birds, rabbits, horses, goats, gerbils, rats, mice, and amphibians, others are considered as companion animals. Read Report Overview - https://www.transparencymarketresearch.com/companion-animal-specialty-drugs-market.html According to the American Society for the Prevention of Cruelty to Animals (ASPCA) defines companion animal to be domesticated or domestically-bred whose emotional, physical, social, and behavioral
Companion Animal Vaccine – Improving The Health Of Companion Animals In A Cost …
The companion animal vaccines market is expected to witness significant growth during the forecast period due to launch of vaccines for companion animals. For instance, in December 2017, Zoetis Inc. announced the launch of Vanguard CIV H3N2/H3N8, the latest vaccine in the company’s canine influenza virus (CIV) portfolio. The new bivalent vaccine helps protect dogs against the two strains of the virus known to be circulating in the U.S. Moreover, the
Companion Diagnostics Market - Easing of Regulatory Policies to Drive Global Dem …
Companion diagnostics include two types of tests namely tests which are developed along with target drugs and the other developed after the commercialization of drugs. Companion diagnostics combined with targeted therapeutics are being seen as a major breakthrough in the personalized medicine field. Companies operating in the companion diagnostics market are seeking an effective growth strategy in the development of this concept drug-diagnostic interaction as the healthcare sector is shifting
Global Companion Diagnostics Market
The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic (CDx) test
Global Companion Diagnostics – Growth Companion for Personalized Medicine
Companion Diagnostics: Growth Companion for Personalized Medicine Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the therapy.
Companion diagnostics Market: Companion diagnostic are used to determine patient …
The few companion diagnostics are already available in the market for specific types of cancer and many are already under clinical development. Companion diagnostics test depends on finding a specific biomarker in the patient and hence biomarker presence or absence determines whether or not the patient will respond to the treatment. This test require a biopsied tissue to access the expression of biomarker protein or mutant or aberrant genes. Companion